tion Trial (SPIRIT), with an intended sample size of 2000 patients in the USA and Canada, had to be closed due to insuffi cient enrollment. At the moment, there are two clinical trials ongoing: the 'Prostate Cancer Intervention Versus Observation Trial (PIVOT)' study, designed [4] by the Department of Veterans Affairs and National Cancer Institute (EEUU) with a sample size of 1000 patients under age 75; and the Prostate Testing for Cancer and Treatment Study (ProtecT) [5] , performed in the UK, which has attempted to improve recruitment by embedding this trial within qualitative research to make it more acceptable to patients and clinicians. It will be some years before the results of these clinical trials are available and in the meantime doctors face the problem of briefi ng patients on the many therapeutic options, as recently published in the New York Times (26 February 2008: "A review of prostate cancer leaves men in a muddle").
Even though evidence from randomised clinical trials comparing treatments is not yet available, the Agencies for the Evaluation of Medical Technology of Quebec and Catalonia [6, 7] conducted a systematic review of studies that compared different treatments and included determination of pre-and post-treatment PSA. Two of the studies [8, 9] in that review evaluated the three main treatment options (radical prostatectomy, prostate brachytherapy and external radiotherapy) and found overall biochemical progressionfree survival rates at fi ve years of 70% [8] and 85% [9] , respectively. More importantly, for low-risk patients, neither study found a statistically signifi cant difference between the 3 treatment groups. These results weaken the established criterion of radical prostatectomy as the fi rst option of treatment for localised prostate cancer and lend support to the greater use of brachytherapy and external beam radiotherapy.
The upshot of all this uncertainty is that other aspects of treatment -in particular, health-related quality of life (HRQL)-have become increasingly important, especially if we bear in mind that locally-confi ned prostate cancer can be asymptomatic whereas treatment can have serious side effects. Studying the side effects and HRQL may help men and clinicians to decide between treatment options. In this context, interest in understanding how treatments will affect HRQL has grown enormously, and the first longitudinal studies including the main treatment options with pre-treatment evaluation and mid-term follow-up have been published recently. Two of these were conducted in the USA [10, 11] and one in Spain, the 'Spanish Multicentric Study on Prostate Cancer' [12] , with similar results to those from the USA: sexual dysfunction and urinary incontinence were greatest in the prostatectomy group, impairment of bowel function was highest in the external beam radiotherapy group and urinary irritation symptoms were greatest in the brachytherapy group.
Indeed The Spanish Multicentric group has been very active since it was created several years ago. The group recently published preliminary results of the 3-year follow-up [13] for HRQL in prostate cancer and also developed the Spanish-language version of the Expanded Prostate Cancer Index Composite (EPIC) [14] , a questionnaire designed to evaluate the impact of prostate cancer treatment on patient quality of life. We are now working on the 5-year followup (grant PI08/90090 ISCIII -FEDER) to assess long-term effects of these treatments.
To conclude, the aim of this editorial is to highlight the relevant research of this group in order to illustrate what can be accomplished when Spanish researchers apply their knowledge, skills, and resources in a focused way. There is no reason why we should not be at the forefront of research and publication in our respective areas of expertise. The opportunity to provide leadership on the wider world stage is available, but it is up to us to seize the initiative, to expand our horizons, and above all, to act-with energy, passion, and conviction.
